A comparative study for Shugan Jieyu Capsule and Fluoxetine in the treatment of depression

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900026443

Enrollment

Unknown

Registered

2019-10-10

Start date

2019-11-01

Completion date

Unknown

Last updated

2019-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression

Interventions

Shugan Jieyu Capsule Group:Give Shugan Jieyu Capsules 4 capsules/day

Fluoxetine dispersible tablets:Give fluoxetine dispersible tablets 1 tablet / day

Normal control group:No

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with mild to moderate depression, Consistent with the International Statistical Classification of Diseases and Related Health Problems (ICD-10) diagnostic criteria for mild to moderate depressive episodes, Hamilton Depression Scale 24 (HAMD-24) 7 <score < 24 points; Han nationality; 18 years old <= age <= 60 years old, right-handed, gender is not limited; clear consciousness; meet the conditions of magnetic resonance scanning (no Metal materials in the body, such as pacemakers, metal dentures, etc.; no claustrophobia; sign informed consent. Normal control group: 18 years old <= age <= 60 years old, right-handed, gender is not limited; no major physical illness and history of craniocerebral trauma; no family history of positive family related; no significant psychological disorder detected by SCL-90 ( SCL-90 total score does not exceed 160 points, or the number of positive items does not exceed 43), Hamilton Depression Scale 24 (HAMD-24) score <7 points; in line with the magnetic resonance scan (no metal materials in the body, such as metal Dentures, pacemakers, etc.; no claustrophobia); sign informed consent.

Exclusion criteria

Exclusion criteria: Have aphasia, indiscriminate, visual or hearing impairment, dementia or other symptoms, unable to complete psychological tests; combined with severe organic disease (severe heart, lung, liver and kidney dysfunction, severe infection, chronic inflammatory disease, tumor, blood Disease); used any psychiatric and neurological drugs within 2 months prior to enrollment, or undergoing systemic psychotherapy or electroconvulsive therapy within 2 months; combined with other mental disorders and substance abusers; those with severe suicidal tendencies ( HAMD-24 suicide project score > 2).

Design outcomes

Primary

Measure	Time frame
MRI;HAMD;SCL-90;Wechsler Memory, Intelligence Scale;	—

Countries

China

Contacts

Public ContactYong Xu

The First Clinical Medical College /First Hospital of Shanxi Medical University

xuyongsmu@vip.163.com+86 18234016125

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026